Eric Sorscher
Emory University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Eric Sorscher as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:08 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT05743946 · Trikafta for Patients With Non-cystic Fibrosis BronchiectasisEmory University · completed · Non-cystic Fibrosis Bronchiectasis · principal investigator
- Ph2NCT03506061 · Trikafta in Cystic Fibrosis PatientsEmory University · completed · Cystic Fibrosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 10 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Discovery of novel mechanisms that impact CFTR translation and contribute to cystic fibrosis pathogenesisR01HL136414 · NHLBI · EMORY UNIVERSITY · fiscal years 2018 to 2025 · $551,534 awarded in 2025Same name and institution; not confirmed by an ID
- P & F SorscherP30DK125013 · NIDDK · EMORY UNIVERSITY · fiscal years 2020 to 2022 · $85,728 awarded in 2022Same name and institution; not confirmed by an ID
- Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicineR01HL139876 · NHLBI · EMORY UNIVERSITY · fiscal years 2018 to 2022 · $736,241 awarded in 2022Grant number is on one of their registry trials
- Intratumoral generation of F-Ade to ablate low growth fraction HNSCCR01DE026941 · NIDCR · EMORY UNIVERSITY · fiscal years 2017 to 2021 · $442,836 awarded in 2021Same name and institution; not confirmed by an ID
- Phase I - II Study of Ad/PNP(IND14271,1/19/10)for HNSCC(OrphanDrugDes,14-4438,6/8/15)R01FD005746 · FDA · EMORY UNIVERSITY · fiscal years 2018 to 2021 · $125,000 awarded in 2021Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:08 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis.Hum Gene Ther · 2001134 citationsRCR 3.1
- Gene therapy for cystic fibrosis using cationic liposome mediated gene transfer: a phase I trial of safety and efficacy in the nasal airway.Hum Gene Ther · 199466 citationsRCR 1.7
- Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis.J Pediatr · 200241 citationsRCR 1.5
- Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.Ann Oncol · 201536 citationsRCR 1.1